Leukemia and Lymphoma Program

Physicians and researchers at the Cancer and Blood Diseases Institute of Cincinnati Children’s Hospital Medical Center offer clinical research studies for patients with leukemia and lymphoma.

View a complete list of current clinical trials or narrow your search specifically for those related to leukemia and lymphoma.

Acute Lymphoblastic Leukemia

Therapy for First Relapse

• AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
• ADVL1212: A Phase I Study of Crizotinib in Combination with Conventional Chemotherapy for Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma (ALCL)
• SGN19A-001: A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma
•  20130320-BITE: An Open-Label, Multi-center, Expanded Access Protocol of Blinatumomab for the Treatment of Pediatric and Adolescent Subjects with Relapsed and/or Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (Rialto Study)

Therapy for Newly Diagnosed Very High Risk Disease

•  AALL1231: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
• AAML1531: Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
• ANHL12P1: A Randomized Phase II Trial of Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL)
• ANHL1131: Intergroup Trial for Children or Adolescents with B-Cell Non-Hodgkin Lymphoma (NHL) or Mature B-Cell Leukemia B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients\

Therapy for Second or Greater Relapse

• SIR-MO-1101: Pilot Study of Sirolimus Plus Multi-agent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma.
• ADVL1212: A Phase I Study of Crizotinib in Combination with Conventional Chemotherapy for Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma (ALCL)
• CLDK378X2103: A Phase I, Open-Label, Dose Escalation Study of LDK378 in Pediatric Patients with Malignancies that have a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)
• SGN19A-001: A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma
• CPX-MA-1202: A Phase I/Pilot Study of CPX-351 for Children, Adolescents and Young Adults with Recurrent or Refractory Hematologic Malignancies
•  20130320-BITE: An Open-Label, Multi-center, Expanded Access Protocol of Blinatumomab for the Treatment of Pediatric and Adolescent Subjects with Relapsed and/or Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (Rialto Study)

Acute Myeloid Leukemia and Myelodysplasia

Therapy for New Diagnosis High Risk Disease

• AAML1331: A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-trans Retinoic Acid

Therapy for Relapse

•  AAML1522: A Phase II, Multicenter, single-arm, open label study to evaluate the activity, safety, and pharmacokinetics of Lenalidomide (REVLIMID®) in Pediatric subjections from 1 to 18 Years of age with Relapseor Refractory Acute Myeloid Leukemia
• ADVL1212: A Phase I Study of Crizotinib in Combination with Conventional Chemotherapy for Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma (ALCL)
• CPX-MA-1202: A Phase I/Pilot Study of CPX-351 for Children, Adolescents and Young Adults with Recurrent or Refractory Hematologic Malignancies
• SGN19A-001: A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma

Hodgkin's and Non-Hodgkin's Lymphoma

Therapy for Relapse

• EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
• ADVL1414: A Phase 1 Study of Selinexor (KPT-330, IND#125052), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
• ADVL1412: A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab
• AHOD1221: A Phase I/II Study of Brentuximab Vendotin in combination with Gemcitabine for Pediatric and Young Adult Patients with Relapsed or Refractory Hodgkin Lymphoma
• ADVL1212: A Phase I Study of Crizotinib in Combination with Conventional Chemotherapy for Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma (ALCL)
• CPX-MA-1202: A Phase I/Pilot Study of CPX-351 for Children, Adolescents and Young Adults with Recurrent or Refractory Hematologic Malignancies